According to StrategyHelix, the ophthalmic drugs market in China is expected to increase by US$ 2,245 million during 2021-2027, expanding at a CAGR of 8.7% during the forecast period.
This 2nd edition of Ophthalmic Drugs Market in China includes following information:
Market Overview: Market Size, Grow Rate, CAGR
Application: Dry Eye Syndrome (DES), Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Glaucoma, Persistent Corneal Epithelial Defects (PED), Anti-infectives, Anti-allergic Agents, Others
Competitors: Novartis International AG, Chengdu Kanghong Pharmaceutical Group Co., Ltd., Santen Pharmacetical Co., Ltd., URSAPHARM Arzneimittel GmbH, Shenyang Xingqi Pharmaceutical Co., Ltd., Others
Years Considered: this database covers the period 2016-2027
After you have placed your order and your payment has been authorized, the database download link will be emailed to you instantly. Please note that the database is supplied in an Excel spreadsheet.
StrategyHelix’ data is protected by copyright and cannot be supplied to any third party.
StrategyHelix DataPass produces a series of directories and databases on industries, economies and consumers in Western and Central Europe, North and South America, Asia Pacific, the Middle East and Africa. DataPass aims at helping our clients analyze market context and identify future trends.